Marmara University

marmara.edu.tr

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

573

Active

115

Phase 3

2

Total enrollment

88,905

Pipeline matrix

Showing 20 of 20 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Adrenaline—————1
0.9 % sodium chloride—————1
Romosozumab and Denosumab Combination Therapy—————1
Romosozumab Prefilled Syringe [Evenity]—————1
Denosumab—————1
Rivaroxaban plus immunosupression—————1
propofol—————3
Saline—————1
Dexamethasone—————1
Prilocaine—————1
Bupivacaine—————1
Postoperative Analgesia Protocol—————1
Opioid-free Anesthesia—————1
Opioid based Anesthesia—————1
Sevofluorane—————1
Phenol—————1
Tociliuzumab—————1
Infliximab—————1
Adalimumab—————1
Certolizumab Pegol—————1

Next readouts

  • 2025-11
  • 2026-06-01
  • 2026-10-15
  • 2026-12-01
  • 2026-12-09
  • 2026-12-15
  • 2027-04-01
  • 2027-06
  • 2027-10-01
  • 2027-12-15

Top conditions

  • Cerebral Palsy15
  • Stroke13
  • Pain13
  • Periodontitis12
  • Anxiety10
  • Central Sensitisation9
  • Postoperative Pain8
  • Lumbar Radiculopathy8

Frequently asked questions about Marmara University

How many clinical trials does Marmara University have on ClinicalTrials.gov?
Marmara University is listed as the lead sponsor on 573 clinical trials in ClinicalTrials.gov, 115 of which are currently active (recruiting, enrolling, or ongoing).
How many of Marmara University's trials are in Phase 3?
2 of Marmara University's trials are in Phase 3, spread across 20 active drug programs.
What therapeutic areas does Marmara University focus on?
Marmara University's most-studied conditions on ClinicalTrials.gov are Cerebral Palsy, Stroke, Pain, Periodontitis, Anxiety.
When are Marmara University's next clinical trial readouts?
Marmara University has 10 upcoming primary-completion readouts tracked here; the soonest is “Comparison of Ganglion Impar Radiofrequency Ablation and Phenol Neurolysis Techniques for Chronic Coccydynia Treatment”, expected around 2025-11.